Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension-Results from the EUTOPIA trial

Atherosclerosis

Volumn 209, Issue 1, 2010, Pages 184-188

  Lorenzen, Johan M ^a   Neunhöffer, Henrike ^a   David, Sascha ^a   Kielstein, Jan T ^a   Haller, Hermann ^a   Fliser, Danilo ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Angiotensin II receptor blocker; Arterial hypertension; Atherosclerosis; ICAM 1; Inflammation markers; Osteopontin; Statin; VCAM 1

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; OLMESARTAN; OSTEOPONTIN; PLACEBO; PRAVASTATIN; VASCULAR CELL ADHESION MOLECULE 1;

ADD ON THERAPY; ADULT; ARTICLE; BEDTIME DOSAGE; CARDIOVASCULAR INFLAMMATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESSENTIAL HYPERTENSION; EVENING DOSAGE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; OSTEOPONTIN; PRAVASTATIN; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAZOLES;

EID: 77049106565     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.09.009     Document Type: Article

References (48)

1. Stirban A.O., and Tschoepe D. Cardiovascular complications in diabetes: targets and interventions. Diabetes Care 31 February (Suppl. 2) (2008) S215-S221
2. Sesso H.D., Buring J.E., Rifai N., et al. C-reactive protein and the risk of developing hypertension. JAMA 290 December 10 (22) (2003) 2945-2951
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 January 14 (2) (1999) 115-126
4. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 January 28 (3) (2003) 499-511
5. Blake G.J., Rifai N., Buring J.E., and Ridker P.M. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 108 December 16 (24) (2003) 2993-2999
6. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 April 21 (16) (2005) 1685-1695
7. Aird W.C. Phenotypic heterogeneity of the endothelium. I. Structure, function, and mechanisms. Circ Res 100 February 2 (2) (2007) 158-173
8. Aird W.C. Phenotypic heterogeneity of the endothelium. II. Representative vascular beds. Circ Res 100 February 2 (2) (2007) 174-190
9. Rangaswami H., Bulbule A., and Kundu G.C. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16 (2006) 79-87
10. Rangaswami H., Bulbule A., and Kundu G.C. JNK1 differentially regulates osteopontin-induced nuclear factor-inducing kinase/MEKK1-dependent activating protein-1-mediated promatrix metalloproteinase-9 activation. J Biol Chem 280 (2005) 19381-19392
11. Rangaswami H., Bulbule A., and Kundu G.C. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J Biol Chem 279 (2004) 38921-38935
12. O'Regan A., and Berman J.S. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 81 (2000) 373-390
13. 1 to osteopontin. Matrix Biol 24 (2005) 418-427
14. 1 integrin-osteopontin interaction. Exp Cell Res 258 (2000) 342-351
15. Denhardt D.T., and Guo X. Osteopontin: a protein with diverse functions. FASEB J 7 (1993) 1475-1482
16. Patarca R., Saavedra R.A., and Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit Rev Immunol 13 (1993) 225-246
17. Yu X.Q., Fan J.M., Nikolic-Paterson D.J., et al. IL-1 up-regulates osteopontin expression in experimental crescentic glomerulonephritis in the rat. Am J Pathol 154 (1999) 833-841
18. Ricardo S.D., Franzoni D.F., Roesener C.D., Crisman J.M., and Diamond J.R. Angiotensinogen and AT(1) antisense inhibition of osteopontin translation in rat proximal tubular cells. Am J Physiol Renal Physiol 278 (2000) F708-F716
19. Hullinger T.G., Pan Q., Viswanathan H.L., and Somerman M.J. TGFbeta and BMP-2 activation of the OPN promoter: roles of smad- and hox-binding elements. Exp Cell Res 262 (2001) 69-74
20. Diamond J.R., Kreisberg R., Evans R., Nguyen T.A., and Ricardo S.D. Regulation of proximal tubular osteopontin in experimental hydronephrosis in the rat. Kidney Int 54 (1998) 1501-1509
21. Ashizawa N., Graf K., Do Y.S., et al. Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. J Clin Invest 98 (1996) 2218-2227
22. Takemoto M., Yokote K., Yamazaki M., et al. Enhanced expression of osteopontin by high glucose. Involvement of osteopontin in diabetic macroangiopathy. Ann N Y Acad Sci 902 (2000) 357-363
23. Sodhi C.P., Phadke S.A., Batlle D., and Sahai A. Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: role of osteopontin. Am J Physiol Renal Physiol 280 (2001) F667-F674
24. Ikeda T., Shirasawa T., Esaki Y., Yoshiki S., and Hirokawa K. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 92 (1993) 2814-2820
25. Giachelli C.M., Base N., Almeida M.M., et al. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 92 (1993) 1686-1696
26. Isoda K., Kamezawa Y., Ayaori M., et al. Osteopontin transgenic mice fed a high-cholesterol diet develop early fatty-streak lesions. Circulation 107 (2003) 679-681
27. Kurata M., Okura T., Watanabe S., Fukuoka T., and Higaki J. Osteopontin and carotid atherosclerosis in patients with essential hypertension. Clin Sci (Lond) 111 November (5) (2006) 319-324
28. Ohmori R., Momiyama Y., Taniguchi H., et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 170 (2003) 333-337
29. Kato R., Momiyama Y., Ohmori R., et al. High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention. Arterioscler Thromb Vasc Biol 26 (2006) e1-e2
30. Arishiro K., Hoshiga M., Negoro N., et al. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol 49 April 3 (13) (2007) 1482-1489 [Epub 2007 March 21]
31. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 March 23 (9311) (2002) 995-1003
32. Dandona P., Kumar V., Aljada A., et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 88 September (9) (2003) 4496-4501
33. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 January 20 (3) (2000) 145-153
34. Koh K.K., Ahn J.Y., Han S.H., et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 42 September 3 (5) (2003) 905-910
35. Khan B.V., Navalkar S., Khan Q.A., Rahman S.T., and Parthasarathy S. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease. J Am Coll Cardiol 38 November 15 (6) (2001) 1662-1667
36. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 November 20 (21) (2008) 2195-2207 [Epub 2008 November 9]
37. Albert M.A., Danielson E., Rifai N., and Ridker P.M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 July 4 (1) (2001) 64-70
38. Plenge J.K., Hernandez T.L., Weil K.M., et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106 September 17 (12) (2002) 1447-1452
39. Jialal I., Stein D., Balis D., et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103 April 17 (15) (2001) 1933-1935
40. Fliser D., Buchholz K., and Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110 August 31 (9) (2004) 1103-1107
41. Roberts W.L., Moulton L., Law T.C., et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 47 March (3) (2001) 418-425
42. Brassard P., Amiri F., Thibault G., and Schiffrin E.L. Role of angiotensin type-1 and angiotensin type-2 receptors in the expression of vascular integrins in angiotensin II-infused rats. Hypertension 47 January (1) (2006) 122-127 [Epub 2005 December 5]
43. Yin B.L., Hao H., Wang Y.Y., Jiang Y.J., and Xue S. Downregulating osteopontin reduces angiotensin II-induced inflammatory activation in vascular smooth muscle cells. Inflamm Res 58 February (2) (2009) 67-73
44. Kadoglou N.P., Gerasimidis T., Moumtzouoglou A., et al. Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis. Eur J Vasc Endovasc Surg 35 June (6) (2008) 661-668
45. Takemoto M., Kitahara M., Yokote K., et al. NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells. Br J Pharmacol 133 May (1) (2001) 83-88
46. Tanaka N., Momiyama Y., Ohmori R., et al. Effect of atorvastatin on plasma osteopontin levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 26 August (8) (2006) e129-e130
47. Li C., Sun B.K., Lim S.W., et al. Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy. Transplantation 79 June 15 (11) (2005) 1522-1529
48. Shen S.I., Kotamraj P.R., Bhattacharya S., Li X., and Jasti B.R. Synthesis and characterization of RGD-fatty acid amphiphilic micelles as targeted delivery carriers for anticancer agents. J Drug Target 15 (2007) 51-58